A new drug developed by a French company reduces mortality by “more than 50%”.

An innovative stroke treatment developed by a French company reduces patient mortality “More than 50%”, according to a clinical trial announced on Tuesday 23 January by France Inter. A team of French researchers published these excellent results from a phase 3 clinical trial of stroke treatment in the prestigious journal The Lancet Neurology on Tuesday. A drug intended for use in cases of stroke, Glenzocimab, was developed by Actor Biotech, a French company.

The Acticor Biotech study was conducted on more than 160 stroke patients in six European countries. These patients received glenzosimab, a drug that thins the blood, in addition to thrombolysis, a treatment already used for stroke. “It’s a drug that will prevent clot formation. But it won’t increase the risk of bleeding.”Explains France Inter Professor Michel Mazigie, Head of the Department of Neurology at Lariboisière Hospital in Paris.

Another cause of death in France

When a stroke occurs, there is a lot of bleeding in the brain. With a reduction in intracranial hemorrhages, the risk of death decreases mechanically. This study shows. Researchers found that “Patients who did not take the drug had a 19% mortality rate”Professor Mikael Mazigi explains. “And patients receiving the drug had a mortality rate that dropped to 8%,” either “More than 50% reduction in mortality”.

Stroke, the leading cause of disability and second cause of death in France, affects around 130,000 people each year.